may minimize. Unfortunately, to our knowledge, only a few studies have evaluated the de-escalation for VAP in a clinical setting (1, 6 -8) .
Previous guidelines classify patients as "early-onset" or "late-onset" depending on whether the infection begins within 48 -96 hrs after intubation (9) . Briefly, patients with early-onset VAP are treated with narrow-spectrum antibiotics, whereas those with late-onset VAP receive broadspectrum antibiotics. Because many patients are admitted after a recent hospitalization or from a healthcare facility, new guidelines consider risk factors for infection with multiple-drug resistant pathogens in patients with early-onset VAP (4) . Consequently, these guidelines may potentially increase the number of potential patients treated with broad-spectrum antibiotics.
However, many patients with lateonset VAP, in our opinion, can be treated empirically with limited-spectrum antibiotics. Indeed, rational empirical antimicrobial therapy should be based on local patterns of antimicrobial susceptibility, patient history, and current medical status. Knowledge of local bacteriologic pattern can increase the likelihood that appropriate initial antibiotic treatment will be prescribed (10) . If the rate of multipledrug resistant pathogens is low in a specific unit, the bacteria responsible for late-onset VAP in patients without comorbidity and prior hospitalization may be susceptible to antibiotics without activity against Pseudomonas aeruginosa. This strategy can be effective only if the treatment is reassessed early, once the results of cultures are available. Hence, a careful screening of patients should allow clinicians to restrict antibiotic overuse and decrease the selection pressure on local ecology.
In our unit, an integrative strategy of dynamic management of antibiotic treatment for patients with VAP has been designed. This strategy includes a rational use of empirical antibiotic therapy considering local patterns of susceptibility of pathogens, prior history of patients, and clinical status, followed by an early reassessment to focus on the bacteria responsible for VAP. De-escalation is performed systematically if possible. Escalation is considered when an early clinical response is not obtained or initial treatment is inappropriate. Patients without risk factors for multiple-drug resistant pathogens are treated with narrowspectrum antibiotics, whatever the time of onset of VAP. We evaluated this integrative strategy with the following objectives: a) to assess the rate of appropriateness of empirical treatment in a cohort of patients with VAP; b) to assess the practice of de-escalation in this cohort of patients; and c) to assess the impact of this strategy on the bacteria responsible for recurrence of VAP.
MATERIALS AND METHODS
The present study was conducted in a 16-bed intensive care unit of an 800-bed university hospital (Hôpital Nord, Marseille, France). Informed consent and approval by the Ethics Committee were waived due to the observational nature of the study. During a 3-yr period (January 2001 to January 2004), all patients admitted to the intensive care unit requiring tracheal intubation and mechanical ventilation for Ն48 hrs were eligible for this investigation.
Patients. Patients who developed VAP were included in the study cohort. Patients with associated septic shock were not included. The diagnosis of VAP was established when the following criteria were fulfilled: a) bronchial purulent sputum; b) body temperature Ͼ38°C or Ͻ36°C; c) white blood cells Ͼ10,000 mm Ϫ3 or Ͻ4000 mm Ϫ3 ; d) chest radiograph showing new or progressive infiltrates; e) presence of at least one microorganism at a concentration of Ն10 4 colony-forming units·mL Ϫ1 on the bronchoalveolar lavage or 10 5 colony-forming units·mL Ϫ1 on tracheal aspirates. We excluded episodes in which the final diagnosis was rejected or undetermined due to the presence of an alternative cause or in which no agreement on diagnosis was reached.
The unit is set up on a closed organizational format, with two weekly staff meetings, including a meeting with the microbiology physicians. The plan of care was decided during the daily round by the attending physician in agreement with the primary physician. Trauma patients received selective digestive decontamination consisting of polymixin E, gentamicin, and amphotericin B, as described elsewhere (11) . For the first 3 days, systemic cefazolin (1 g ϫ 3 daily) was given to all trauma patients. Selective digestive decontamination medication was started on the admission day and continued until the patients were weaned from mechanical ventilation. Stress-ulcer prophylaxis was used in patients with past medical history significant for ulcer, as described elsewhere (12) . Patients received early enteral nutrition if possible. They underwent mechanical ventilation with the ventilator set in volume-controlled mode. Heat and moisture exchanger bacterial filters (Gibeck, Stockholm, Sweden) were inserted between the endotracheal tube and the ventilator circuit except for patients with acute respiratory distress syndrome (ARDS). Patients were positioned semirecumbent.
Empirical Antimicrobial Therapy. The antimicrobial therapy was administered according to our local written guidelines, which are summarized in Figure 1 . Empirical antimicrobial therapy was started just after microbiological samples were collected. Ceftriaxone or amoxicillin-clavulanate was used in the patients with early-onset VAP (Ͻ5 days) without recent prior hospitalization including longterm care facilities and prior antibiotic treatment. If intracellular infection was suspected, macrolides were added at the discretion of the attending physician. Gentamicin was combined with ␤-lactam in the patients with severe sepsis. The patients who developed late-onset VAP (Ն5 days) without prior hospitalization (within 21 days), prior administration of antibiotics (within 10 days) except for surgical prophylaxis and selective digestive decontamination, and signs of severity defined by the occurrence of ARDS or severe sepsis were treated with ceftriaxone (limited spectrum). In other cases, ␤-lactam antibiotics with activity against P. aeruginosa (piperacillin-tazobactam or ceftazidime) were used at the discretion of rounding physicians (broad spectrum). Carbapenems were kept as last-line therapy. An aminoglycoside (amikacin) or a quinolone (ciprofloxacin) was added when criteria for severe sepsis were present. Vancomycin was prescribed when oxacillin-resistant Staphylococcus aureus (ORSA) was suspected: previous colonization in a patient's microbiological samples or other patients in the unit with ORSA infection. Empirical antimicrobial therapy was systematically reassessed from the moment the microbiological results were available (i.e., on days 2-3). Microbiological findings were used to determine whether the empirical treatment targeted the isolated bacteria. The clinical status of patients was evaluated taking into account the evolution of prior organ dysfunction and lactate levels. According to the antimicrobial susceptibility of the isolated bacteria and the improvement or not of clinical status, a decision was made to either perform escalation, perform de-escalation, or maintain the previously prescribed empirical treatment.
Definitions. "Broad-spectrum antibiotics" will refer thereafter for antibiotics with activity against P. aeruginosa including imipenemcilastatin, piperacillin-tazobactam, ceftazidime, or ciprofloxacin, whereas "broad-spectrum antimicrobial therapy" will designate a combination of antibiotics with activities against P. aeruginosa and ORSA. In particular, adding aminoglycosides to ␤-lactam was considered as a broadspectrum therapy. Limited-spectrum antibiotics will only refer to ␤-lactam without activity against P. aeruginosa (essentially, ceftriaxone and amoxicillin-clavulanate).
Inappropriate empirical antimicrobial therapy was defined as follows: a) absence of antimicrobial agents directed against a specific class of microorganisms; and b) administration of an antimicrobial agent to which the microorganism responsible for VAP was resis-tant (13) . Clinical resolution was defined as a complete resolution of all signs and symptoms of pneumonia in conjunction with improvement or stabilization of all abnormalities on the chest radiograph. The Clinical Pulmonary Infection Score (CPIS) was used to assess the clinical response of patients to the treatment (14) . Deaths were related to VAP if they occurred before any objective response to antimicrobial therapy or if the pulmonary infection was considered a contributing factor to death in patients with comorbidity (15) . The excess of intensive care unit mortality caused by inappropriate empirical antimicrobial therapy was determined by subtracting the intensive care unit crude mortality rate when the patients had already received appropriate empirical antimicrobial therapy from the crude mortality rate of patients with inappropriate treatment in whom the antibiotic treatment was modified after the cultures demonstrated isolation of a resistant organism.
De-escalation of antibiotic therapy consists either of deleting one of the antibiotics of the prescribed combination or, whenever possible, using a ␤-lactam antibiotic with a narrower spectrum of activity (16) . Criteria for narrowing the antimicrobial regimen are based on the results of susceptibility testing of isolated bacteria. Escalation of antibiotic therapy consists either of adding an antibiotic of another family to the pivotal ␤-lactam left or using a ␤-lactam antibiotic with a broader spectrum of activity. The criteria for escalation were the lack of susceptibility of isolated bacteria on cultures and/or inappropriate clinical response, defined by a CPIS Ͼ8 on day 3 or/and the occurrence of severe sepsis.
Severe sepsis was defined according to the criteria of Bone et al (17) . The presence of ARDS, defined using criteria of the AmericanEuropean Consensus Conference on ARDS, was also noted (18) . Recurrence of VAP was defined by the occurrence of a new episode of VAP after clinical resolution of the first episode.
Bacteriology. Data were extracted from the microbiology laboratory database. In all patients admitted to the intensive care unit, cultures from nose, throat, trachea (intubated patients), and urine were obtained at admission and thereafter twice weekly. When indicated, samples from catheters, wounds, and blood were taken and cultured. All samples were submitted to routine Gram staining. The material was inoculated onto free growth culture media and onto selective differential media for the isolation of Gram-negative and Gram-positive microorganisms. Cultures were incubated at 35°C and examined after 18 -24 hrs. Identification of microorganisms and testing of antibiotic sensitivity were performed according to internationally accepted laboratory practice. Primary cultures were obtained by using the following media. For nares, pharynx, respiratory secretions, and wounds, we used chocolate polyvitex agar, Colombia calcium nutrient sheep blood agar, Drigalski agar, and Sabouraud, gentamicin, and chloramphenicol agar (if yeasts were found by direct examination). For detection of Haemophilus influenzae, H. influenzae test medium agar was used (Bio Merieux, Marcy l'Etoile, France). Importantly, cross-transmission of epidemic strains was a rare event in this intensive care unit during the study period.
Variables. The following variables were recorded at intensive care unit admission: age, gender, comorbidities, prior hospitalization, case mix, Glasgow Coma Scale score, prior antibiotic treatment within 10 days, and Simplified Acute Physiology Score (SAPS) II (range, 0 -174; higher scores indicate more severe illness) (19) . The following criteria were collected on the day of sampling collection: body temperature, white blood cells, PaO 2 /FIO 2 ratio, lactate plasma level Ͼ2 mmol·L Ϫ1 . The duration of mechanical ventilation and the intensive care unit length of stay were also collected.
Statistical Analysis. A descriptive analysis was performed. Quantitative data were compared using Student's t-test. Qualitative data were compared using chi-square test with Yates correction or Fisher's exact test when necessary. Univariate analysis was performed to determine the risk factors for receiving an inappropriate empirical antimicrobial therapy. The alpha level was set at p Ͻ .05. Analysis of mortality was adjusted to SAPS II according to the Mantel-Haenszel method. A multivariate analysis quantified the respective effect of each variable according to appropriateness of the empirical antimicrobial therapy and to the CPIS on day 8. A stepwise logistic regression was performed (forward method, likelihood ratio). Explanatory variables in the logistic regression were variables identified as potential risk factors by the univariate analysis with a p Ͻ .2 and those known as risk factors by the scientific community. The condensed model was presented with crude odds ratio (OR) and 95% confidence interval (CI).
RESULTS
Appropriateness of Empirical Antimicrobial Therapy. Among 2,848 admissions during the 3-yr period of study, 115 patients requiring tracheal intubation for Ն48 hrs developed VAP (Table 1) . Bacteria responsible for VAP are presented in Table 2 . Empirical antimicrobial therapy was appropriate in 100 patients (87%), 79% for early-onset VAP and 91% for late-onset VAP. Characteristics of patients receiving inappropriate empirical antimicrobial therapy are shown in Table  3 . Independent risk factors for receiving an inappropriate treatment were infections due to high-risk bacteria (P. aeruginosa, Acinetobacter baumanii, ORSA) (OR, 21; 95% CI, 3.1-140), age Ͼ45 yrs (OR, 10; 95% CI, 1.7-58), and SAPS II Ͼ40 (OR, 5.3; 95% CI, 1.0 -27).
Outcome of Patients.
Outcome of patients was impaired by an inappropriate empirical treatment (Fig. 2) . The rate of intensive care unit mortality was significantly higher in the patients in whom empirical therapy was inappropriate than in those in whom treatment was appropriate (47 vs. 20%, p ϭ .04) (Fig. 3 ). This represents a 23% excess of mortality, even after adjustment to the SAPS II (OR, 3.1; 95% CI, 1.1-8.5). Death was directly related to VAP in 14 patients, including four patients in whom empirical treat- 2) were significantly associated with a CPIS Ͼ6 on day 8. The mortality rate of patients with increased or stable CPIS from day 3 to day 8 was 43%, compared with 8% for those with decreasing CPIS during the same period (p ϭ .001).
Reevaluation of Antimicrobial Therapy. Monotherapy was used in 75 (66%) VAP episodes. A limited-spectrum empirical antimicrobial therapy was used in 79 patients (69%), including 53 (70%) patients with late-onset VAP. Four patients who were treated with ceftriaxone or amoxicillin-clavulanate received at admission one dose of erythromycin or metronidazole. Subsequently, these patients were considered as treated with limited-spectrum antibiotics but not monotherapy. Aminoglycosides were combined with ␤-lactam in 26 patients (22%), and glycopeptides were used empirically in five patients.
The empirical antimicrobial therapy was de-escalated in 48 patients (42%) on day 3 (3-5), respectively in 26% and 72% of patients with early-and late-onset VAP (Fig. 4) . This de-escalation consisted of discontinuing the combination of antibiotics in 24 patients, using a narrower spectrum antibiotic to replace the ␤-lactam of the empirical therapy in nine patients, and both discontinuing the combination and narrowing the spectrum of ␤-lactam in 15 patients (Fig. 4) . Of note, the empirical antimicrobial therapy was de-escalated in 54% of VAP episodes due to P. aeruginosa, A. baumanii, and ORSA, whereas de-escalation was done in 39% of VAP due to other bacteria. In three patients in whom de-escalation was performed, therapy was upgraded again due to poor clinical response. Among the 48 patients in which treatment was deescalated, mortality was of 18%, compared with 11% in those in which treatment was unchanged (p ϭ .15).
By contrast, empirical treatment was escalated in 27 patients (23%) on day 4 (3-7). In seven of these 27 patients, the pathogens were resistant to the empirical antimicrobial therapy, whereas in four patients, the bacteria were not included in the spectrum of this treatment. A poor clinical response, before the pathogens responsible for VAP were identified, led to escalation in 16 other patients. Among six of them, treatment was de-escalated after the identification of pathogens. The median duration of the antibiotic treatment was of 8 (7-11) days, depending on the appropriateness of empirical antimicrobial therapy (8 [7] [8] [9] [10] vs. 10 [7] [8] [9] [10] [11] [12] [13] [14] days, p Ͻ .05). Finally, 22 recurrences of VAP were observed, including eight (36%) episodes due to P. aeruginosa, A. baumanii, and ORSA. These recurrences were not related to an inadequacy of the antimicrobial therapy. Only three of them were observed in the group of patients who underwent de-escalation.
DISCUSSION
The present study shows that, with the use of limited-spectrum antibiotics in 70% of patients, empirical antimicrobial therapy was appropriate in 87% of patients. In addition, de-escalation was possible in 42% of patients whereas escalation was required in 23% of cases. Of interest, high-risk bacteria were responsible for only 40% of recurrent VAP.
Appropriateness of empirical antimicrobial therapy is crucial since we found, like others previously, that inappropriate treatment is associated with an increased mortality rate (19) . Our appropriateness rate for empirical antimicrobial therapy (100 patients, i.e., 87%) is higher than that obtained in prior studies (3, 20) . We note that adjustment of treatment was unnecessary in 40 patients after bacteria identification with susceptibility testing, probably because of the frequent empirical use of limited-spectrum antibiotics. Actually, inappropriate treatment of infections is often secondary to the lack or violation of protocols (1) . The judicious choice of antibiotics is crucial in critically ill patients (21) . In our intensive care unit, the antibiotic choices are determined in accordance with microbiologist physicians. These choices are consigned in our edited protocols, which are available on a numeric form at the intensive care unit intranet site. By contrast, in many studies, the selection of antibiotics was left to the discretion of the attending physician (3, 20) . Interestingly, the four patients whose death was related to VAP received treatments in violation of our guidelines. In most other cases, inappropriate treatments were due to the administration of antibiotics without activity against P. aeruginosa (n ϭ 4), A. baumanii (n ϭ 4), or ORSA (n ϭ 3). Hence, a written protocol may be critical to assist the attending physician in deciding to prescribe empirical antibiotics. In addition, better adherence to the local guidelines should improve the performance of empirical treatments.
Appropriateness was obtained in 100 (87%) of patients, although 70% of them received limited-spectrum antibiotics. In a study in which patients with VAP were treated according to edited guidelines, the appropriateness of empirical antibiotics for VAP was of 91%, only 4% more than in the present study (6) . However, 78% of patients were treated with broadspectrum antimicrobial therapy. Despite this antimicrobial therapy, five among their 11 patients in which treatment was inappropriate developed fatal episodes of VAP due to A. baumanii (n ϭ 2), ORSA (n ϭ 1), oxacillin-sensitive Staphylococcus aureus (n ϭ 1), and P. aeruginosa (n ϭ 1). Our protocol restricts the use of antibiotics with an activity against P. aeruginosa to 31% of patients. Such a protocol is aimed at decreasing the selection pressure on bacteria, as well as the cost of treatments. Using the American Thoracic Society guidelines for the management of VAP, appropriateness would be obtained in 89% of cases, compared with 87% with our protocol (4). In addition, we found that infections caused by high-risk bacteria were recognized as an independent risk factor for inappropriate antimicrobial therapy, but this represents only 22 patients of whom nine received an inappropriate antimicrobial therapy (7.8%). This small gain would be probably achieved at the expense of increasing selection pressure and cost, since, according to these guidelines, 55 patients with late-onset VAP would have been treated with a ␤-lactam with activity against P. aeruginosa. To underline the effects of antibiotic use on local ecology, we focused on the bacteria responsible for VAP relapses. High-risk bacteria are responsible for 36% of VAP relapses. Expanding the criteria to multiple-drug resistant bacteria, we found 55% of episodes due these bacteria, compared with 71% in a prior study (22) .
To limit the risk of emergence of antibiotic resistance, our guidelines also require the reappraisal of antimicrobial treatment as soon as the bacteria responsible for VAP are identified. The empirical antimicrobial therapy was maintained unchanged in 40 patients. Escalation was required in 27 patients, including ten patients in whom empirical treatment was inappropriate. Obviously, the lack of effect of treatment on clinical response is a good surrogate for the inappropriateness of empirical treatment. There is also a need for a rapid microbiological response to achieve appropriate therapy within a time frame of 48 hrs (23) (24) (25) . This suggests the need for an early clinical and microbiological reassessment of each patient who develops VAP.
De-escalation was possible in 48 patients. Interestingly, in a prior study focusing on de-escalation, change of antibiotics was documented in 56% of cases, including de-escalation in 31% (6) . These numbers are in agreement with our findings, and they suggest that de-escalation is feasible in many patients with VAP. Our results showed the lack of deleterious effect on survival. One should note a striking difference, since empirical treatment was de-escalated in 54% of VAP cases due to high-risk pathogens, compared with 3% in the prior study (6) . Hence, deescalation is a real-life concept that can be applied to high-risk pathogens, including nonfermenting Gram-negatives like Pseudomonas. In addition, de-escalation was implemented in patients treated with limited-spectrum antimicrobial therapy (i.e., ceftriaxone or amoxicilline-clavulanate), because the identified pathogens were susceptible to amoxicillin or methicillin.
The last interesting finding of our study is that a short duration of antibiotic treatment (about 10 days) for VAP does not appear to impair outcome of patients. A study showed that among patients who received appropriate initial empirical therapy, comparable clinical effectiveness against VAP was obtained with the 8-and 15-day treatment regimens. There was a possible exception of those developing nonfermenting Gram-negative bacillus infections (26) . These findings were not available during the study period, but our guidelines already recommended shortduration treatment (10 days). However, the present results provide new data on this issue. Indeed, the patients with VAP due to P. aeruginosa were treated more frequently with an inappropriate empirical antimicrobial treatment than those with VAP due to other bacteria. However, when antibiotic treatment was appropriate, no difference was observed in terms of clinical response to treatment. By contrast, the clinical response of the patients who were appropriately treated for VAP due to S. aureus remained significantly poorer than that of patients with VAP due to other bacteria. These results suggest that longer duration of treatment may be required for VAP due to S. aureus (27) (28) (29) . However, the study was not designed to assess such issue, and future investigations are needed to test this hypothesis.
Our study has several limitations. First, patients in shock were excluded from the study. However, the appropriateness of the empirical antimicrobial therapy for septic shock patients was assessed in a prior study including 107 patients. In this population, a source of infection was documented in 78 patients. Sixty-nine (89%) of these patients were treated with an appropriate antimicrobial therapy, whereas treatment was deescalated in 64% of cases (30) . Second, the implications of selective digestive decontamination in trauma patients were not explored. In a prior case-control study, we showed that empirical antimicrobial treatment for VAP was appropriate in 89% of trauma patients in whom selective digestive decontamination was applied. In addition, high-risk pathogens were rarely isolated (31) . However, the true effect of selective digestive decontamination remains difficult to determine. Third, the value of regular surveillance cultures for guiding the empirical therapy was not evaluated in the present study. However, systematic samples are collected on admission and twice a week in our intensive care patients, and they are useful especially in the patients carrying high-risk bacteria. Indeed, the regular surveillance of cultures is critical to revise the protocol according to local ecology changes. On this topic, the past published results were rather negative, but this might be due to a low prevalence of surveillance (e.g., once weekly) (32, 33) . Indeed, more recent data seem to show a benefit of using these regular cultures to guide empirical treatments (34 -36) .
CONCLUSION
The present study shows that knowledge of local ecology and consideration of patient medical history and clinical conditions lead to prescription of a rational empirical antimicrobial therapy for VAP using limited-spectrum antibiotics. In addition, our data clearly show that deescalation is feasible in 40% of patients. This strategy may reduce the emergence of resistant bacteria, which in turns reduces the need for broad-spectrum antibiotics, breaking the vicious circle of antibiotic overuse. However, there is a need for unconditional adherence to local guidelines to provide the best care to patients.
